What Proportion of BRCA–Associated Breast Cancer Is Human Epidermal Growth Factor 2–Low and Eligible for Additional Targeted Therapy?
Forester E, Belsare A, Kim D, Whitaker K, Obeid E, Goldstein L, Bleicher R, Daly M, Williams A. What Proportion of BRCA–Associated Breast Cancer Is Human Epidermal Growth Factor 2–Low and Eligible for Additional Targeted Therapy? Journal Of Surgical Research 2024, 299: 217-223. PMID: 38776577, DOI: 10.1016/j.jss.2024.04.032.Peer-Reviewed Original ResearchTriple negative breast cancerHuman epidermal growth factor 2HER2-lowBreast cancerTargeted therapyMetachronous contralateral breast cancerPathogenic variantsHuman epidermal growth factor 2 statusBRCA-associated breast cancerRetrospective chart review of patientsChart review of patientsContralateral breast cancerBRCA gene statusInvasive breast cancerTargeted therapy optionsReview of patientsHR+/HER2- breast cancerRetrospective chart reviewNegative breast cancerFluorescence in situ hybridizationHER2 dataMetastatic settingTrastuzumab deruxtecanHER2-positiveGrowth factor 2